There are currently 1572 clinical trials in Baltimore, Maryland looking for participants to engage in research studies. Trials are conducted at various facilities, including Johns Hopkins University, Johns Hopkins Hospital, University of Maryland and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Recruiting
The purpose of this study is to evaluate the safety and clinical activity of tislelizumab (an anti-PD-1 antibody) in combination with SX-682 (a CXCR1/2 inhibitor) in subjects with newly diagnosed and surgically resectable pancreatic adenocarcinoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Johns Hopkins SKCCC, Baltimore, Maryland
Conditions: Pancreatic Cancer
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Recruiting
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess ziftomenib, a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib will continue in patients with NPM1-m AML.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia
Coaching Teachers in Bullying Detection and Intervention
Recruiting
The investigators' overall objective is to demonstrate the efficacy of the Bullying Classroom Check-Up (BCCU) on elementary aged students' aggressive and bullying behaviors, teacher practices, and student and teacher relationships. The investigators' principal hypothesis is that the BCCU will improve students' aggression and bullying behaviors and their perceptions of the school climate and relationships in the building as well as teacher practices.
Gender:
All
Ages:
Between 8 years and 99 years
Trial Updated:
03/13/2024
Locations: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
Conditions: Intervention, Control
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
Recruiting
This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
Gender:
All
Ages:
Between 6 years and 16 years
Trial Updated:
03/12/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Hyperphosphatemia Related to Chronic Kidney Disease
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Recruiting
This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
03/12/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Recruiting
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned pembrolizumab monotherapy.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/12/2024
Locations: University of Maryland, Baltimore, Maryland
Conditions: Brain Tumor
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Recruiting
If transplantation using mismatched unrelated donors or non-first-degree relatives could be performed with an acceptable toxicity profile, an important unmet need would be served. Towards this goal, the current study extends our platform of nonmyeloablative, partially HLA-mismatched bone marrow transplant (BMT) and Peripheral Blood Stem Cell Transplant (PBSCT) to the use of such donors, investigating up to several postgrafting immunosuppression regimens that incorporate high-dose Cy. Of central... Read More
Gender:
All
Ages:
Between 6 months and 75 years
Trial Updated:
03/12/2024
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Hematologic Malignancies
Long-Term Clinical, Immunologic, and Virologic Profiles of Children Who Received Early Treatment for HIV
Recruiting
IMPAACT 2028 is an observational prospective study to characterize a cohort of early treated children who may participate in future research related to HIV remission or cure. Up to approximately 250 participants will be in the study for approximately seven years. No intervention is provided in the study.
Gender:
All
Ages:
All
Trial Updated:
03/11/2024
Locations: Johns Hopkins University NICHD CRS (5092), Baltimore, Maryland
Conditions: HIV Infection
A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
Recruiting
This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1. The primary objective is to evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive low-grade glioma (LGG) as measured by objective tumor response rate (CR+PR) within the first 48 weeks (12 cycles) of therapy. There will also be secondary and exploratory objectives listed in the detailed description below.
Gender:
All
Ages:
22 years and below
Trial Updated:
03/08/2024
Locations: Johns Hopkins University (Site 250), Baltimore, Maryland
Conditions: NF1, Low-grade Glioma
Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment
Recruiting
This five-year study will evaluate the effectiveness of the administration of buprenorphine bridge treatment (BBT) to probationers and parolees compared to treatment as usual (TAU), which consists of referral to a community buprenorphine treatment program.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/06/2024
Locations: Division of Parole & Probation, Baltimore, Maryland
Conditions: Opioid Use
Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
Recruiting
The purpose of this study is to determine the maximum tolerated dose of the chemotherapy drugs nab-paclitaxel and gemcitabine when combined with hypofractionated ablative proton therapy for the treatment of locally advanced pancreatic cancer. You will receive proton therapy once a day (Monday - Friday) for 3 weeks. Participants will also receive chemotherapy on each Monday of those three weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/05/2024
Locations: University of Maryland Medical Center/Maryland Proton Treatment Center, Baltimore, Maryland
Conditions: Locally Advanced Pancreatic Cancer
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Recruiting
The study is an extension of two parent studies (MLN0002-3024 [NCT04779307] and MLN0002-3025 [NCT04779320]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.
Gender:
All
Ages:
2 years and above
Trial Updated:
03/05/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Ulcerative Colitis, Crohn's Disease